$19.6 Bn Alzheimer's Disease Global Markets, Therapeutics and Diagnostics to 2029, Profiles of Leading Players - AbbVie, Biogen, Eisai Co, Eli Lilly and Co., and F. Hoffmann-La Roche - ResearchAndMarkets.com

The "Alzheimer's Disease Therapeutics and Diagnostics: Global Markets" report has been added to ResearchAndMarkets.com's offering.

The Alzheimer's Disease Therapeutics and Diagnostics Market was valued at USD 2024 in 9.7 Billion, and is expected to reach USD 2029 by 19.6 Billion, rising at a CAGR of 15.10%.

This report focuses on the global market for Alzheimer's disease (AD) diagnostics and therapeutics, offering an updated review of this rapidly emerging market. In this report, the diagnostic market covers only biomarker tests for AD. Cognitive tests and neuroimaging diagnostic methods assessing structural changes are not part of the market calculations. The diagnostics market segmentation is based on the test type and region.

The increased government funding in neurology research and an ever-growing demand for research focused on drug discovery for the development of novel therapies in neurological disorders are driving the growth of the market.

Alzheimer's disease cannot be prevented, cured, or slowed, and it is a rapidly growing and serious health problem, affecting more than 17 million worldwide. Therapies for AD provide temporary and modest improvements in the well-being of individuals, but none of the approved drugs can modify the course of the disease progression. The immense size of the affected population and lack of appropriate and effective treatment offers a tremendous commercial opportunity for the makers of AD drugs and diagnostics.

The understanding of the underlying reasons and mechanisms involved in AD is very limited. Drug developers have continually failed to demonstrate meaningful clinical benefits of treatment for a myriad of investigational compounds due to stringent regulations. High drug attrition rates and long drug approval times have driven pharmaceutical companies and technology ventures closer to each other for collaborations. Specifically, diagnostic technology companies are rigorously trying to bring about effective biomarker technologies to assist and enhance the drug development process for prospective drug candidates. Regulatory bodies are highly supportive of the use of diagnostic technologies in order to improve drug attrition rates.

Despite the recurring failures in the development of novel therapies for AD, the global markets are demanding new and more effective disease attenuating treatments, with first-in-class approvals. This expectation and the increasing incidence of AD associated with the aging population are driving the market.

The therapeutics segment covers pharmacological treatments (drugs) only. This report does not cover alternative treatment options, such as procedural interventions. Additionally, many medications are used "off-label" to manage non-cognitive symptoms, such as agitation and depression, associated with dementia due to AD. This report does not cover off-label drugs used in the treatment of Alzheimer's. The therapeutics market segmentation is based on purpose, drug class, drug type, disease stage, and region.

An analysis of clinical trials, innovations, opportunities, and the latest trends in the AD diagnostics and therapeutics market are also discussed in the report.

Report Includes

• 38 data tables and 80 additional tables
• Analyses of the trends in the global market for Alzheimer's disease (AD) therapeutics and diagnostics, with market revenue data (sales figures) from 2021 and 2022, estimates for 2023, forecasts for 2024-2025, and projected CAGRs through 2029
• Estimates of the size of the global market and revenue growth prospects, along with a market share analysis by type, therapeutic application, drug classification, mechanism of action, disease state of indication and region
• Facts and figures pertaining to key market dynamics, technological advances, regulations, and the impact of macroeconomic factors
• Identification of diagnostic tools and equipment; scientific and technological frameworks; drug profiles, clinical groundworks; and coverage of global developments
• Information on products that are currently available for the diagnosis and treatment of Alzheimer's disease, as well as the promising new drug candidates and diagnostic imaging agents
• An analysis of patents, emerging trends and the industry structure, including companies' market shares and rankings, strategic alliances, M&A activity and a venture funding outlook
• Overview of sustainability trends and ESG developments, with emphasis on consumer attitudes, and the ESG scores and practices of leading companies
• Profiles of leading companies, including AbbVie Inc., Biogen, Eisai Co. Ltd., Eli Lilly and Co., and F. Hoffmann-La Roche Ltd.

Key Attributes:

Key Topics Covered:

Chapter 1 Executive Summary

• Market Outlook
• Scope of Report
• Market Summary

Chapter 2 Market Overview

• Alzheimer's Disease Overview
• Alzheimer's Disease Pathophysiology
• AD and Amyloid Cascade
• AD and Tauopathy
• AD and Neurotransmitter Systems
• Diagnosis of AD
• Cognitive Status Testing
• Brain Imaging
• Lumbar Puncture
• Blood-Biomarker Tests
• Genetic Testing
• Pharmaceutical Treatment of AD

Chapter 3 Market Dynamics

• Market Dynamics Snapshot
• Market Drivers
• Growing Incidence of AD
• High Unmet Need
• Growing Focus on Biomarkers in Diagnosis and Drug Development
• Increasing Public and Private investment in Neuroscience
• Growing Public Awareness and Early Diagnosis
• Large Number of Drugs in Late-Stage Clinical Trials
• Market Restraints
• High Costs of Diagnostics and Novel Therapies
• Patent Expirations of Branded Drugs and Emergence of Generics
• High Failure Rate in Drug Development

Chapter 4 Emerging Technologies and Developments

• Emerging Technologies/Trends
• Blood Tests for AD Screening and Diagnosis
• Disease Modifying Small-Molecule Drugs
• Re-purposed Drugs
• AI and Machine Learning
• Pipeline Analysis
• Overview
• Therapeutic Purpose Type
• Novel AD Therapeutics in Development in Phase 3
• By Target Type
• By Disease State
• Novel PET Radiotracers in Development

Chapter 5 Market Segmentation Analysis

• Segmentation Breakdown
• Market Analysis, by Test Type
• AD Biomarker Tests Market, by Test Type
• AD Therapeutics Market, by Therapeutic Purpose
• AD Therapeutics Market, by Drug Class
• AD Therapeutics Market, by Drug Type
• AD Therapeutics Market, by Disease Stage
• Geographic Breakdown
• Market Analysis, by Region
• North America
• Europe
• Asia-Pacific
• Rest of the World (RoW)

Chapter 6 Competitive Intelligence

• AD Therapeutics
• Alzheimer's Generic Drug Market
• Alzheimer's Branded Drug Market
• Donepezil
• Rivastigmine
• Galantamine
• Memantine
• Combination Therapy (Memantine and Donepezil)
• AD Diagnostics
• Overview
• Product Launches/Approvals in the AD Diagnostics Market

Chapter 7 Appendix

• Methodology
• Sources
• Abbreviations

Company Profiles

• Abbvie Inc.
• Alpha Cognition
• Alzpath Inc.
• Aurobindo Pharma
• Biogen
• C2N Diagnostics
• Corium Llc.
• Diadem Srl
• Eisai Co. Ltd.
• F. Hoffmann-La Roche Ltd.
• H.U. Group Holdings Inc.
• Laboratory Corporation Of America Holdings
• Lilly
• Otsuka Holdings Co. Ltd.
• Quest Diagnostics Inc.

For more information about this report visit https://www.researchandmarkets.com/r/t6vs0y

About ResearchAndMarkets.com

ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

View source version on businesswire.com: https://www.businesswire.com/news/home/20250221466375/en/